Home › Funds › ORBIMED ADVISORS LLC › STTK
ORBIMED ADVISORS LLC position in STTK
SHATTUCK LABS INC · Health Care
ORBIMED ADVISORS LLC reported holding 6,306,127 shares of STTK (SHATTUCK LABS INC) in its Q2 2026 13F filing — a position valued at US$43.8M, representing 0.88% of its reported portfolio and ranking #35 among its reported holdings. ORBIMED ADVISORS LLC has disclosed STTK holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's STTK position evolved
ORBIMED ADVISORS LLC first disclosed a stake in STTK in Q3 2025 at 6,306,127 shares (US$15.1M). The position peaked in Q2 2026 at 6,306,127 shares, worth US$43.8M. Across 4 filings, ORBIMED ADVISORS LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 6,306,127 shares valued at US$43.8M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 6.31M | $15.07M | New |
| Q4 2025 | 6.31M | $23.02M | Hold |
| Q1 2026 | 6.31M | $40.55M | Hold |
| Q2 2026 | 6.31M | $43.76M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About STTK and 13F data
STTK (SHATTUCK LABS INC) is a Health Care company. 57 other funds we track also report a position in STTK — the largest reported positions include Redmile Group, LLC (US$47.8M), Prosight Management, LP (US$41.3M), Frazier Life Sciences Management, L.P. (US$26.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding STTK
- Redmile Group, LLC 6.89M sh · $47.83M · Q2 2026
- Prosight Management, LP 5.96M sh · $41.35M · Q2 2026
- Frazier Life Sciences Management, L.P. 3.75M sh · $26.02M · Q2 2026
- NEXTBio Capital Management LP 3.73M sh · $25.87M · Q2 2026
- Deep Track Capital, LP 3.71M sh · $25.72M · Q2 2026
- CLARK ESTATES INC/NY 1.43M sh · $9.93M · Q2 2026
- Boxer Capital Management, LLC 1.00M sh · $6.94M · Q2 2026
- S&G Foundation 435.75K sh · $3.02M · Q2 2026
- West Tower Group, LLC 191.62K sh · $1.31M · Q3 2026
- LBJ Family Wealth Advisors, Ltd. 82.18K sh · $560.00K · Q3 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held STTK?
ORBIMED ADVISORS LLC has disclosed STTK holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is ORBIMED ADVISORS LLC's current position in STTK?
As of Q2 2026, ORBIMED ADVISORS LLC holds 6.31M shares of STTK (SHATTUCK LABS INC), valued at $43.76M, representing 0.88% of its reported portfolio and ranking #35.
Has ORBIMED ADVISORS LLC been buying or selling STTK?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC held unchanged its position in STTK. The position peaked in Q2 2026 at 6.31M shares.
Which other funds hold STTK?
Other major institutional holders of STTK include Redmile Group, LLC, Prosight Management, LP, Frazier Life Sciences Management, L.P., among 57 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.